Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
Mohamad-Ali Salloum, PharmD • March 7, 2026
Share
Pharmacology
PK/PD
Buprenorphine: A Simple, Step‑by‑Step Journey Through the Body
A clear guide for pharmacy students learning PK/PD the smart way. Short chunks. Visual cues. A quick quiz at the end.
Strong grip
= high MOR affinity
Weak push
= partial agonism
1) Quick History
Where Buprenorphine Came From
Developed in the late 1960s from thebaine(a poppy plant derivative), buprenorphine was designed to give useful opioid effects with a safer profile. It binds very strongly to μ‑opioid receptors (MORs) but only partially activates them.
Opioid Use Disorder (OUD)
Chronic Pain (select cases)
2) The Patient
Why Buprenorphine Is Needed
Classic opioid withdrawal may include: runny nose, yawning, dilated pupils, goosebumps, stomach cramps, anxiety, and fast heartbeat — all due to under‑stimulation of MORs.
⚠️
Critical rule:
Start buprenorphine only when moderate withdrawal
is present. If given too early, it can displace a full agonist and cause precipitated withdrawal.
3) Absorption
How Buprenorphine Enters the Body
Sublingual is the most common route because swallowing leads to extensive first‑pass metabolism. Under the tongue, it reaches systemic circulation directly.
Bioavailability
~30–50% (sublingual)
T max
1–4 hours
Protein binding
~96%
Half‑life
~24–37 hours
Naloxone in combo products has minimal sublingual absorption; it mainly matters if injected.
Hover the button to simulate absorption
4) Distribution
Where the Drug Travels
- Crosses the blood–brain barrier(high lipophilicity)
- Accumulates in fat — slow release over time
- Highly protein‑bound(~96%)
- Crosses the placenta and appears in breast milk
Memory hook: “Couch‑potato molecule”
— likes fat, stays longer.
5) Pharmacodynamics
What the Drug Does
MOR: Partial agonist
KOR: Antagonist
DOR: Antagonist/weak partial agonist
ORL‑1: Partial agonist
Show intracellular actions
- ↓ cAMP
- ↓ presynaptic Ca²⁺ → ↓ pain neurotransmitter release
- ↑ K⁺ efflux → hyperpolarization
✅
Clinical effects:
reduces withdrawal and cravings, provides analgesia, ceiling effect on respiratory depression
, and functionally blocks other opioids (very high MOR affinity). PET studies suggest ~ 70% MOR occupancy
helps suppress withdrawal and block opioid effects.
6) Metabolism
How the Body Breaks It Down
- Phase I – CYP3A4: buprenorphine → norbuprenorphine (active, poor CNS entry)
- Phase II – UGT1A1 & UGT2B7: glucuronidation → water‑soluble metabolites
Memory line:
“3A4 cuts, UGTs clean.”
CYP3A4 inhibitors ↑ levels
CYP3A4 inducers ↓ levels
Liver disease: adjust
Kidney disease: modest effect
7) Elimination
How It Leaves the Body
- ~70% via feces (major)
- ~30% via urine (mostly metabolites)
- Some enterohepatic recirculation
8) A → Z Story
One‑Glance Journey (Sublingual Dose)
A.
Patient arrives in moderate withdrawal.
B.
Sublingual film dissolves → absorbed through oral mucosa.
C.
Avoids first‑pass metabolism → enters systemic circulation.
D.
Travels in blood (mostly protein‑bound).
E.
Free drug crosses into the brain.
F.
Strong MOR binding → partial
activation.
G.
Withdrawal/cravings decrease; ceiling effect improves safety.
H.
Liver enzymes break it down (CYP3A4 + UGTs).
I.
Metabolites go to bile and kidneys.
Z.
Excreted in feces (major) and urine (minor).
9) Key Clinical Tips
High‑Yield for Students
- Start only in moderate withdrawal to avoid precipitated withdrawal.
- Typical OUD maintenance: 12–16 mg/day (individualize per labeling/clinical response).
- Watch CYP3A4 interactions(inhibitors ↑ levels; inducers ↓ levels).
- CNS depressants increase respiratory risk despite the ceiling.
- Acute pain is trickier due to receptor blockade — use multimodal strategies.
Check Yourself
Quick Quiz: Can You Recall the Essentials?
1) Why is sublingual buprenorphine preferred over oral swallowing?
2) The best time to start buprenorphine is:
3) Which statement is correct?
4) Main elimination route?
5) Quick metabolism memory aid:
References :
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. McGraw‑Hill; 2018.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology. 9th ed. Elsevier; 2020.
- Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59‑S77.
- SAMHSA. TIP 63: Medications for Opioid Use Disorder. Rockville, MD; 2018.
- Suboxone® (buprenorphine/naloxone) sublingual film. U.S. Prescribing Information. Indivior.
- Kuhlman JJ Jr, et al. Human pharmacokinetics of sublingual buprenorphine. J Anal Toxicol. 1996;20(6):369‑378.
- Rouguieg‑Malki K, et al. Contribution of UGTs and CYP3A4 to buprenorphine metabolism. Drug Metab Dispos. 2011;39(12):2059‑2066.
- Dahan A, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627‑632.
- Greenwald MK, et al. Buprenorphine dose, MOR occupancy, and blockade of opioid effects. Neuropsychopharmacology. 2003;28(11):2000‑2009.
- Lund IO, et al. Pregnancy outcomes on buprenorphine vs methadone. Addiction. 2013;108(2):255‑262.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
References: Aggarwal D, Naik J, Lindquist DH. Biphasic Model of Addiction: Neurobehavioral Adaptations . Curr Behav Neurosci Rep. 2025;12:25. 1 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the brain disease model of addiction . Lancet Psychiatry. 2025;12(6):469–474. 2 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the BrainDisease Model of Addiction (Accepted Version). University of Sheffield; 2025. Unterrainer HF. Addiction, attachment, and the brain: a focused review of empirical findings and future directions . Front Hum Neurosci. 2025;19. 3 Vaswani M. Neurobiology of Addiction . Addiction Behavioral Conference 2025. Magnus Group.
This guide breaks down why your body reacts the way it does, how misinterpretation fuels anxiety, and the CBT tools designed to help you understand (and stop fearing) your own physical sensations.
This article explains why avoidance is so powerful, how it silently shapes your emotions and behaviors, and evidence‑based strategies that help you break the cycle.
Are you having Negative Automatic Thoughts (NATs)? We got you 💆♂️
Learn how to break the vicious cycle by addressing your behaviors!
Low Mood is NOT random!
Learn how CBT rewires thoughts, emotions, and behaviors—and test your knowledge with a quick quiz.
A clear, engaging walkthrough of fentanyl’s pharmacokinetics and pharmacodynamics—from administration to metabolism and excretion—designed for pharmacy and medical students, with visuals, summaries, and an interactive quiz.
Understand Aspirin easily with this blog post.